Recent 8-K filings for GKOS

• May 4, 2026, 7:59 PM ET other materiality 0.15 neutral item 7.01item 9.01

  Glaukos files 8-K to announce investor presentation; no material new data

  The 8-K states the investor presentation (Exhibit 99.1) will be used in meetings with investors and stakeholders.

• April 29, 2026, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Glaukos Q1 record sales $150.6M (+41% YoY); raises FY2026 guidance to $620-635M

  Record net sales $150.6M (+41% YoY, +39% constant currency).

• March 2, 2026, 6:59 PM ET other materiality 0.25 neutral item 7.01item 9.01

  Glaukos posts Q4 2021 investor presentation with no material new disclosures

  Company made available a March 2026 investor presentation via 8-K Item 7.01.

• February 17, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  Glaukos Q4 record sales $143.1M (+36% YoY); reaffirms FY2026 guidance $600-620M

  Q4 net sales $143.1M (record), +36% YoY; full year $507.4M, +32% YoY.

• January 13, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  Glaukos reports preliminary Q4 2025 net sales ~$143M (+36% YoY); reaffirms FY2026 guidance $600-620M

  Q4 2025 net sales ~$143M (+36% YoY); FY2025 net sales ~$507M (+32% YoY).

• November 10, 2025, 6:59 PM ET other materiality 0.10 neutral item 7.01item 9.01

  Glaukos files 8-K furnishing November 2025 investor presentation; no material updates disclosed

  Investor presentation dated November 2025 is furnished under Regulation FD and will be used in meetings.

• October 29, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  Glaukos Q3 revenue $133.5M (+38% YoY); raises 2025 guide, introduces 2026 outlook

  Record net sales $133.5M, up 38% YoY; U.S. Glaucoma sales $80.8M (+57% YoY).

• August 12, 2025, 7:59 PM ET other material materiality 0.15 neutral item 7.01item 9.01

  Glaukos posts investor presentation for August 2025; no specific financial updates visible

  Investor presentation dated August 2025 made available via SEC filing and company website.

• July 30, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 7.01item 9.01

  Glaukos Q2 record net sales $124.1M (+30% YoY); raises FY 2025 guidance to $480-486M

  Record net sales $124.1M, up 30% YoY; glaucoma sales $103.5M (+36%), U.S. glaucoma $72.3M (+45%).

• June 3, 2025, 7:59 PM ET other materiality 0.10 positive item 5.07

  Glaukos stockholders elect directors, approve say-on-pay, ratify EY at annual meeting

  Elected Class I directors Foley, Hoffmeister, and Kliman; broker non-votes of 3,221,029.

• May 14, 2025, 7:59 PM ET other materiality 0.10 neutral item 7.01item 9.01

  Glaukos files routine investor presentation; no material new information disclosed

  Filed Form 8-K with an investor presentation dated May 2025.

• April 30, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 7.01item 9.01

  Glaukos Q1 net sales record $106.7M (+25% YoY); net loss narrows to $0.32/sh from $0.82

  Record Q1 net sales $106.7M, up 25% reported and 26% constant currency vs $85.6M last year.

• March 12, 2025, 7:59 PM ET other material materiality 0.15 neutral item 7.01item 9.01

  Glaukos posts March 2025 investor presentation; no specific updates disclosed

  Investor presentation filed under Item 7.01 Regulation FD; no earnings or guidance included.

• February 20, 2025, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 7.01item 9.01

  Glaukos Q4 record net sales $105.5M, +28% YoY; guides FY2025 $475-485M

  Q4 net sales record $105.5M, +28% YoY; glaucoma segment $84.1M (+39%).

• January 14, 2025, 6:59 PM ET other materiality 0.10 neutral item 7.01item 9.01

  Glaukos files January 2025 investor presentation; no specific new data disclosed in excerpt

  Filing under Item 7.01 for Regulation FD; presentation to be used in investor meetings.

• December 9, 2024, 6:59 PM ET other material materiality 0.40 neutral item 7.01

  Glaukos receives $53.2M from capped call unwind on convertible notes

  Option counterparties paid $53.2M to Glaukos under Capped Call Unwind Agreements.

• December 3, 2024, 6:59 PM ET other material materiality 0.60 neutral item 1.01item 9.01

  Glaukos partially unwinds capped calls on 2027 convertible notes; receives cash based on VWAP

  Entered into unwind agreements for 50% of capped call transactions associated with $287.5M 2.75% convertible notes due 2027.

• November 15, 2024, 6:59 PM ET other materiality 0.20 neutral item 7.01item 9.01

  Glaukos files routine investor presentation for November 2024; no specific new data

  Company furnished an investor presentation dated November 2024 under Regulation FD.

• November 4, 2024, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 7.01item 9.01

  Glaukos Q3 revenue $96.7M (+24% YoY), raises 2024 guidance to $377-379M

  Record Q3 net sales of $96.7M (+24% YoY); glaucoma segment $76.0M (+30%), corneal health $20.6M (+5%).

• October 11, 2024, 7:59 PM ET debt materiality 0.55 neutral item 8.01item 9.01

  Glaukos redeems all $57.5M of 2.75% Convertible Notes due 2027; conversion by Dec 13, 2024

  Company issued notice to redeem all $57.5M aggregate principal of 2.75% Convertible Senior Notes due 2027.

• August 9, 2024, 7:59 PM ET other material materiality 0.15 neutral item 7.01item 9.01

  Glaukos provides investor presentation; no material new facts in filing text

  Presentation dated August 2024; full content not available in provided text.

• August 2, 2024, 7:59 PM ET other material materiality 0.50 neutral item 2.02item 9.01

  Glaukos files 8-K/A to correct $3.3M debt cost accounting; GAAP EPS overstated by $0.06

  Corrected reclassification of $3.3M unamortized debt issuance costs from interest expense to additional paid-in capital for the June 2024 convertible note exchange.

• July 31, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 7.01item 9.01

  Glaukos reports record Q2 sales $95.7M (+19% YoY), raises FY2024 guidance

  Record net sales of $95.7M, up 19% reported / 20% constant currency YoY.

• June 28, 2024, 7:59 PM ET other material materiality 0.75 neutral item 3.02item 8.01

  Glaukos exchanges $230M of 2.75% convertible notes for 4.25M shares of common stock

  Exchanged $230M principal of 2.75% Convertible Senior Notes due 2027 for 4,253,423 common shares and cash.

• June 14, 2024, 7:59 PM ET other material materiality 0.85 neutral item 3.02item 8.01item 9.01

  Glaukos exchanges $230M of 2.75% Convertible Notes due 2027 for common stock

  Glaukos entered agreements to repurchase $230M of its 2.75% Convertible Senior Notes due 2027.

• June 5, 2024, 7:59 PM ET other material materiality 0.50 neutral item 5.02item 5.07item 9.01

  Glaukos stockholders approve amended 2015 omnibus incentive plan; directors elected

  Stockholders approved Amended and Restated 2015 Omnibus Incentive Plan, reducing share reserve to 4.7M new shares plus rollover of outstanding awards.

• May 20, 2024, 7:59 PM ET other materiality 0.10 neutral item 7.01item 9.01

  Glaukos furnishes May 2024 investor presentation with no specific financial updates

  Company furnished a standard investor presentation as Exhibit 99.1; no new financial results or guidance disclosed.

• May 1, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Record Q1 net sales of $85.6M (+16% YoY); raised 2024 guidance to $357-$365M

  Glaucoma segment sales $67.2M (+20% YoY); Corneal Health $18.4M (+4% YoY).

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.53 · Most common event earnings

11 positive 0 negative 17 neutral

source · GKOS on sec.gov